Aldehydic components of Cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 20, 2008, Pages 9176-9183

  Tsuji Naito, Kentaro ^a  

^a KoMasaldl and Masami Saitoh: Souken Corporation   (Japan)

Author keywords

Cinnamomum zeylanicum; NFATc1; Osteoclastogenesis; RANKL

Indexed keywords

ALDEHYDE DERIVATIVE; CINNAMON EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ARTICLE; BARK; CELL VIABILITY; CINNAMOMUM ZEYLANICUM; CONTROLLED STUDY; DRUG ISOLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; ONCOGENE C FOS; OSTEOCLAST; OSTEOPENIA; PROTON NUCLEAR MAGNETIC RESONANCE;

ALDEHYDES; ANIMALS; CELL DIFFERENTIATION; CELL LINE; CINNAMOMUM ZEYLANICUM; DOWN-REGULATION; MICE; MOLECULAR STRUCTURE; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PLANT BARK; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; SIGNAL TRANSDUCTION;

CINNAMOMUM VERUM;

EID: 53249103052     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.09.036     Document Type: Article

References (38)

1. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21 (2000) 115
2. Rodan G.A., and Martin T.J. Therapeutic approaches to bone diseases. Science 289 (2000) 1508
3. Suda T., Takahashi N., and Martin T.J. Modulation of osteoclast differentiation. Endocr. Rev. 13 (1992) 66
4. Asagiri M., and Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 40 (2007) 251
5. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., McCabe S., Elliott R., Scully S., Van G., Kaufman S., Juan S.C., Sun Y., Tarpley J., Martin L., Christensen K., McCabe J., Kostenuik P., Hsu H., Fletcher F., Dunstan C.R., Lacey D.L., and Boyle W.J. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. U S A. 97 (2000) 1566
6. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., Daro E., Smith J., Tometsko M.E., Maliszewski C.R., Armstrong A., Shen V., Bain S., Cosman D., Anderson D., Morrissey P.J., Peschon J.J., and Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev. 13 (1999) 2412
7. Wong B.R., Josien R., Lee S.Y., Vologodskaia M., Steinman R.M., and Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 273 (1998) 28355
8. Galibert L., Tometsko M.E., Anderson D.M., Cosman D., and Dougall W.C. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J. Biol. Chem. 273 (1998) 34120
9. Matsumoto M., Sudo T., Saito T., Osada H., and Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem. 275 (2000) 31155
10. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., Pando M.P., Asano T., Verma I.M., Oda H., Nakamura K., and Tanaka S. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J. Cell Biol. 148 (2000) 333
11. Johnson R.S., Spiegelman B.M., and Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71 (1992) 577
12. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J., Wagner E.F., Mak T.W., Kodama T., and Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3 (2002) 889
13. Mühlbauer R.C., and Li F. Effect of vegetables on bone metabolism. Nature 401 (1999) 343
14. Park C.K., Lee Y., Chang E.J., Lee M.H., Yoon J.H., Ryu J.H., and Kim H.H. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL. Biochem. Pharmacol. 75 (2008) 2175
15. Yu S., Chen K., Li S., and Zhang K. In vitro and in vivo studies of the effect of a Chinese herb medicine on osteoclastic bone resorption. Chin. J. Dent. Res. 2 (1999) 7
16. Kim C., Ha H., Lee J.H., Kim J.S., Song K., and Park S.W. Herbal extract prevents bone loss in ovariectomized rats. Arch. Pharm. Res. 26 (2003) 917
17. Dong G.C., Chen H.M., and Yao C.H. A novel bone substitute composite composed of tricalcium phosphate gelatin and drynaria fortunei herbal extract. J. Biomed. Mater. Res. A 84 (2008) 167
18. Nir Y., Potasman I., Stermer E., Tabak M., and Neeman I. Controlled trial of the effect of cinnamon extract on Helicobacter pylori. Helicobacter 5 (2000) 94
19. Tanaka S., Yoon Y.H., Fukui H., Tabata M., Akira T., Okano K., Iwai M., Iga Y., and Yokoyama K. Antiulcerogenic compounds isolated from Chinese cinnamon. Planta Med. 55 (1989) 245
20. Atta A.H., and Alkofahi A. Anti-nociceptive and anti-inflammatory effects of some Jordanian medicinal plant extracts. J. Ethnopharmacol. 60 (1998) 117
21. Dugoua J.J., Seely D., Perri D., Cooley K., Forelli T., Mills E., and Koren G. From type 2 diabetes to antioxidant activity: a systematic review of the safety and efficacy of common and cassia cinnamon bark. Can. J. Physiol. Pharmacol. 85 (2007) 837
22. Lee K.H., and Choi E.M. Stimulatory effects of extract prepared from the bark of Cinnamomum cassia blume on the function of osteoblastic MC3T3-E1 cells. Phytother. Res. 20 (2006) 952
23. Yang J., Chen L.H., Zhang Q., Lai M.X., and Wang Q. Quality assessment of cortex cinnamomi by HPLC chemical fingerprint principle component analysis and cluster analysis. J. Sep. Sci. 30 (2007) 1276
24. He Z.D., Qiao C.F., Han Q.B., Cheng C.L., Xu H.X., Jiang R.W., But P.P., and Shaw P.C. Authentication and quantitative analysis on the chemical profile of cassia bark (cortex cinnamomi) by high-pressure liquid chromatography. J. Agric. Food Chem. 53 (2005) 2424
25. Morozumi S. Isolation purification and antibiotic activity of o-methoxycinnamaldehyde from cinnamon. Appl. Environ. Microbial. 36 (1978) 577
26. Montes-Belmont R., and Carvajal M. Control of Aspergillus flavus in maize with plant essential oils and their components. J. Food Prot. 61 (1998) 616
27. Hasegawa A., Yoshino M., Nakamura H., Ishii I., Watanabe T., Kiuchi M., Ishikawa T., Ohmori S., and Kitada M. Identification of inhibitory component in cinnamon-O-methoxycinnamaldehyde inhibits CYP1A2 and CYP2E1. Drug Metab. Pharmacokinet. 17 (2002) 229
28. Urushibara M., Takayanagi H., Koga T., Kim S., Isobe M., Morishita Y., Nakagawa T., Löeffler M., Kodama T., Kurosawa H., and Taniguchi T. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 50 (2004) 794
29. García Palacios V., Robinson L.J., Borysenko C.W., Lehmann T., Kalla S.E., and Blair H.C. Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 Cells by estrogen and phytoestrogens. J. Biol. Chem. 280 (2005) 13720
30. Wattel A., Kamel S., Mentaverri R., Lorget F., Prouillet C., Petit J.P., Fardelonne P., and Brazier M. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem. Pharmacol. 65 (2003) 35
31. Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., and Delaissé J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation and promotes osteoblast differentiation. Cancer Res. 65 (2005) 9943
32. Takatsuna H., Asagiri M., Kubota T., Oka K., Osada T., Sugiyama C., Saito H., Aoki K., Ohya K., Takayanagi H., and Umezawa K. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J. Bone Miner. Res. 20 (2005) 653
33. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., Leonardi A., Tran T., Boyce B.F., and Siebenlist U. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11 (1997) 3482
34. Iotsova V., Caamaño J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3 (1997) 1285
35. Reddy A.M., Seo J.H., Ryu S.Y., Kim Y.S., Kim Y.S., Min K.R., and Kim Y. Cinnamaldehyde and 2-methoxycinnamaldehyde as NF-kappaB inhibitors from Cinnamomum cassia. Planta Med. 70 (2004) 823
36. Quale J.M., Landman D., Zaman M.M., Burney S., and Sathe S.S. In vitro activity of Cinnamomum zeylanicum against azole resistant and sensitive Candida species and a pilot study of cinnamon for oral candidiasis. Am. J. Chin. Med. 24 (1996) 103
37. Koga T., Matsui Y., Asagiri M., Kodama T., de Crombrugghe B., Nakashima K., and Takayanagi H. NFAT and Osterix cooperatively regulate bone formation. Nat. Med. 11 (2005) 880
38. Loomer P.M., Ellen R.P., and Tenenbaum H.C. Osteogenic and osteoclastic cell interaction: development of a co-culture system. Cell Tissue Res. 294 (1998) 99